Hengrui Medicine is a leading pharmaceutical company based in China with a focus on research, development, manufacturing, and commercialization of innovative and high-quality healthcare products. Hengrui was established in 1970 and listed in Shanghai Stock Exchange in 2000. The company ranks top 30 worldwide by a market capitalization of over 30 billion USD, and is home to more than 21,000 employees worldwide. In May 2018, Hengrui Medicine was listed in Forbes’s top 100 world’s most innovative companies.
In early 2018, Reistone licensed global rights of SHR0302, a JAK1 inhibitor, from Hengrui to development in autoimmune indications. Both companies have formed a long term strategic partnership to bring more innovative medicines to patients globally.
IQVIA commits to providing solutions that enable life sciences companies to innovate with confidence, maximize their opportunities and ultimately drive human health outcomes forward. IQVIA™ was awarded the 2018 Scrip Award for Best Contract Research Organization. This marks the seventh time in the last 10 years that the company has received this award. IQVIA is a major collaborator of Reistone in executing global clinical development.